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Abstract: Insurance coverage policies are a major determinant of patient access to genomic tests.
The objective of this study was to examine differences in coverage policies for guideline-recommended
pharmacogenomic tests that inform cancer treatment. We analyzed coverage policies from eight
Medicare contractors and 10 private payers for 23 biomarkers (e.g., HER2 and EGFR) and multi-gene
tests. We extracted policy coverage and criteria, prior authorization requirements, and an evidence
basis for coverage. We reviewed professional society guidelines and their recommendations for
use of pharmacogenomic tests. Coverage for KRAS, EGFR, and BRAF tests were common across
Medicare contractors and private payers, but few policies covered PML/RARA, CD25, or G6PD.
Twelve payers cover at least one multi-gene test for nonsmall cell lung cancer, citing emerging
clinical recommendations. Coverage policies for single and multi-gene tests for cancer treatments are
relatively consistent among Medicare contractors despite the lack of national coverage determinations.
In contrast, coverage for these tests varied across private payers. Patient access to tests is governed by
prior authorization among eight private payers. Substantial variations in how payers address
guideline-recommended pharmacogenomic tests and the common use of prior authorization
underscore the need for additional studies of the effects of coverage variation on cancer care and
patient outcomes.
Keywords: pharmacogenomics; multi-gene testing; cancer; insurance coverage; tumor markers
1. Introduction
“Personalized medicine” is often described as providing “the right patient with the right drug
at the right dose at the right time” [1]. Genomic tests are increasingly being used in clinical care to
tailor treatment [2]. Approximately $5 billion was spent on genomic testing in 2010; expenditures
are projected to reach $25 billion by 2021 [3]. As of 7 May 2018, there are over 54,538 tests for
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11,169 conditions, 16,415 genes, and 506 laboratories according to the National Institutes of Health’s
Genetic Testing Registry.
Genomic tests may identify individuals at risk of having a toxic response to a drug, thereby
minimizing drug-related adverse events and associated costly consequences such as hospital
admissions [4]. For example, pharmacogenomic tests for HLA-B*1502 can prevent potentially fatal
carbamazepine-induced Stevens–Johnson syndrome. Pharmacogenomics tests can also identify
individuals likely to respond to an intervention if molecular markers of therapeutic response are
identified [5]. Examples include testing for epidermal growth factor receptor (EGFR) to determine
the use of erlotinib in advanced nonsmall cell lung cancer (NSCLC), and KRAS testing to determine
the use of cetuximab in advanced colorectal cancer. To aid clinical decision-making, the Centers for
Disease Control and Prevention (CDC) has categorized genomic tests by level of evidence based
on the Food and Drug Administration (FDA) labeling information, clinical practice guidelines, and
systematic reviews [6]. This system defines about 50 genomic tests with sufficient evidence for clinical
implementation (e.g., KRAS and human epidermal growth factor receptor 2 (HER2) tests to inform use
of cetuximab in colorectal cancer and lapatinib in breast cancer, respectively).
At present, single gene tests cost about $200 whereas multi-gene panels are available for $600 [7].
Inter-related factors at the provider (e.g., specialty, training), patient (e.g., preferences), and health
system (e.g., health insurance) levels affect patient access to genomic tests and related services [8].
Insurance coverage policies and levels of patient cost-sharing are major factors that influence who gets
tested, screened, or treated, and when and which specific test is received [9–12]. To date, there has been
a dearth of research on access to genomic tests. The objective of this study was to examine insurance
coverage policies for guideline-recommended pharmacogenomic tests informing cancer treatment in
order to identify potential access issues. We also sought to determine whether coverage policies are
consistent with major clinical guidelines.
2. Methods
2.1. Pharmacogenomic and Multi-Gene Tests for Cancer
The CDC Office of Public Health Genomics (PHG) categorizes genomic tests by level of evidence
based on the FDA labeling information, clinical practice guidelines, and systematic reviews [6,13].
This system defines ‘tier-1’ genomic tests as those that have a base of synthesized evidence that
supports implementation in practice. We selected non-hereditary cancer-related pharmacogenomic
tests for this study (Table 1). Because some of these tumor markers are now part of multi-gene tests,
we also reviewed coverage policies for multi-gene panels that may govern access to tests for these
biomarkers. The multi-gene panels we included are, however, not in the CDC’s tier-1 category at the
time of the study. We did not include noncancer related multi-gene tests even if they were mentioned
in some coverage policies as they are beyond the scope of this study. Whole genome sequencing and
whole exome sequencing, which cover a large range of genes for noncancer indications, were not
included in this study.
2.2. Guidelines Search and Data Extraction
We also reviewed publicly available guidelines from major professional societies and used them
as a framework for examining coverage policies. The key evidence sources [6] that we included
were: CDC’s PHG and Evaluation of Genomic Applications in Practice and Prevention (EGAPP),
National Cancer Institute (NCI), National Comprehensive Cancer Network (NCCN), American Society
of Clinical Oncology (ASCO), Center for Medical Technology Policy (CMTP), Blue Cross Blue Shield
Association Technology Evaluation Center (BCBSA TEC has recently been replaced by Evidence Street),
American College of Medical Genetics and Genomics (ACMG), Agency for Healthcare Research and
Quality (AHRQ), and the United Kingdom’s National Institute for Health and Clinical Excellence
(NICE). Search terms to identify relevant guidelines included: biomarker names, molecular profiling,
J. Pers. Med. 2018, 8, 19 3 of 15
multi-gene, and panel(s). We extracted the following information in August 2017 from the guidelines
if the guideline recommended a pharmacogenomic test, the criteria, and the evidence basis for
recommendation. Additionally, we extracted recommendations for multi-gene testing including
suggested indications, for comparison with existing coverage policies mentioning multi-gene testing.
Table 1. Study drugs and pharmacogenomic and multi-gene tests.
Biomarker Drug Name Condition FDA Drug Approval Date
KRAS Cetuximab Metastatic colorectal cancer 2/12/2004
Panitumumab Metastatic colorectal cancer 9/27/2006
HER2 Trastuzumab Gastroesophageal junction adenocarcinoma 9/25/1998
Trastuzumab Invasive breast cancer 9/25/1998
Pertuzumab Invasive breast cancer 6/8/2012
Ado-trastuzumab emtansine Metastatic breast cancer 2/22/2013
Lapatinib Advanced or metastatic breast cancer 3/13/2007
BRAF Trametinib Unresectable or metastatic melanoma 5/29/2013
Dabrafenib Unresectable or metastatic melanoma 5/29/2013
Vemurafenib Unresectable or metastatic melanoma 8/17/2011
EGFR Afatinib Metastatic Nonsmall cell lung cancer 7/12/2013
Erlotinib Metastatic Nonsmall cell lung cancer 11/18/2004
ALK Crizotinib Nonsmall cell lung cancer 8/26/2011
BCR-ABL1 Dasatinib Chronic myeloid leukemia/Acute lymphoblastic leukemia 6/28/2006
Imatinib Chronic myeloid leukemia/Acute lymphoblastic leukemia 5/10/2001
Bosutinib Chronic Myeloid Leukemia 9/4/2012
Nilotinib Chronic Myeloid Leukemia 10/29/2007
c-Kit protein Imatinib Gastrointestinal stromal tumors 5/10/2001
PDGFR Imatinib Myelodysplastic/Myeloproliferative diseases 5/10/2001
CD20 Tositumomab Non-Hodgkin’s lymphoma 6/27/2003
G6PD Rasburicase Leukemia, lymphoma 7/12/2002
CD25 Denileukin diftitox Cutaneous T-cell lymphoma 2/05/2009
PML/RARA Arsenic trioxide Acute promyelocytic leukemia 9/25/2000
Cancer Related Multi-Gene Tests CPT Code *
Targeted genomic sequence analysis of 5–50 genes for solid tumors (e.g., ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT,
KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, and RET) 81445
Targeted genomic sequence analysis of 5–50 genes for hematologic malignancies (e.g., BRAF, CEBPA, DNMT3A,
EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, and NOTCH1) 81450
Targeted genomic sequence analysis of 51 or greater genes for solid tumors or hematologic malignancies (e.g., ALK,
BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS,
MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, and RET)
81455
* All Current Procedural Terminology (CPT) codes come from the American Medical Association [14]. FDA-Food
and Drug Administration.
2.3. Medicare Contractors and Private Payers
Medicare is a public, nationwide health insurance program for people who are 65 and older in
the US. We included all eight Medicare contractors: Novitas, National Government Services (NGS),
Cigna Government Services (CGS), First Coast, Noridian, Palmetto, Wisconsin Physicians Service
Insurance Corporation (WPSIC), and Cahaba. Private health insurance is often offered through
an employer or organization but can also be purchased by an individual. We purposively selected
the top US private payers based on the US News & World Report listing of largest third-party
payers [15]: UnitedHealth, Blue Cross Blue Shield-Massachusetts (BCBSA-MA), Anthem, Aetna,
Humana, Health Care Service Corporation (HCSC), Cigna, Highmark, and Independence Blue Cross
(IBX). Together, these private payers cover care for about 182.3 million individuals across the US;
membership estimates were derived from payer websites and Google searches. We also included
Harvard Pilgrim Health Care (HPHC), a regional health plan serving the New England population;
we included HPHC because this study is part of a larger project that includes a qualitative aim [16],
which interviewed patients and providers from this regional health plan.
2.4. Policy Search and Data Extraction
For each payer, we searched for and reviewed coverage policies for 23 pharmacogenomic tests and
cancer-related multi-gene tests (Table 1). Coverage policies were generally publicly accessible through
the payer’s website, related websites (e.g., Centers for Medicare and Medicaid Services, CMS), and/or
using search engines (Google). We searched for biomarker and drug names and key terms including
genetic, gene, pharmacogenomics, biomarker, genomic, multi-gene, panel(s), sequencing, molecular
profiling, and related Current Procedure Terminology (CPT) codes (e.g., 81275 for KRAS; three targeted
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sequencing CPT codes: 81445, 81450, and 81455). We reviewed and extracted the following features
from identified documents: policy name and date; whether the policy covers the test; criteria for
coverage e.g., medical condition; requirements for prior authorization; evidence basis for coverage;
and CPT codes. Reimbursement of a genetic test subject to prior authorization is only permitted if
a physician requests and obtains prior approval from the payer. Prior authorization is commonly
used to manage utilization and costs for medical services and procedures and medications [17].
Our search for single gene tests was last updated in April 2017 and in December 2017 for multi-gene
tests. We verified extracted information of coverage policies with six payers by sending them data
extraction tables of publicly available policies to ensure accurate interpretation.
3. Results
3.1. Biomarker-Related Coverage Policies
Guidelines for single gene tests are generally in consensus; thus, we present our findings on
the relevant coverage policies. Table 2 summarizes Medicare contractor and private payer coverage
policies identified for pharmacogenomic tests guiding cancer treatments, including both the number of
policies that cover the tests (one test may be included in multiple policies) and number of payers that
cover the tests (regardless of how many policies included the test). Policies identified were dated from
August 2015 until February 2017. We did not identify any Medicare national coverage determinations
for study biomarkers. Across eight Medicare contractors, KRAS, BRAF, and EGFR were the most
commonly covered single gene tests; six contractors covered testing for KRAS, while four contractors
covered testing for BRAF and EGFR. Across 10 private payers, KRAS, EGFR, BRAF, and ALK were the
most commonly covered single gene tests; nine payers covered testing for KRAS, EGFR, and ALK, and
eight covered testing for BRAF.
There were differences across payers in terms of the presence of coverage policies for the specific
pharmacogenomic tests included in the study, the content (e.g., covered indications), use of prior
authorization requirements, and the evidence base cited (Table 2). Six private payers required prior
authorization for single gene tests. The most common cited sources of references for coverage included:
NCCN, ASCO, NCI, BCBSA TEC, and AHRQ. Evidence considered by payers for coverage decision
making included randomized controlled trials and other study types, such as systematic reviews
and cohort studies. The CPT codes specified by both Medicare and private payers were similar and
included codes specific to biomarker testing and more general testing codes.
3.2. Multi-Gene Tests Related Guidelines
Few professional society guidelines were identified that specifically related to cancer multi-gene
tests. Table 3 summarizes recent clinical recommendations for multi-gene testing. We identified
substantial variation in the guidelines studied here. Evidence cited by these guidelines also differed
such that no guidelines cited the same studies.
The guidelines that recommended multi-gene tests were NCCN [18], CMTP [19], ASCO [20], and
ACMG [21], with NCCN and CMTP specifically recommending the tests for NSCLC. The CMTP also
recommended such tests for other conditions including rare, uncommon, or stage IV solid tumors,
e.g., lung and pancreatic cancers. These guidelines were largely based on small/medium sized
observational studies, ranging from 31 to 2158 participants in each study [20,22–37]. Blue Cross
Blue Shield Association TEC [38] and United Kingdom’s NICE [39] did not recommend multi-gene
testing in clinical practice; both guidelines, however, were published in 2013, earlier than other
guidelines. Blue Cross Blue Shield Association TEC cited four studies for five cancer indications,
concluding that compelling evidence of clinical utility was not available for multi-gene testing
and issues still exist which need attention, including varying approaches to the interpretation of
multi-gene testing. NICE assessed multi-gene testing for detecting EGFR mutation in adults with
locally advanced or metastatic NSCLC and concluded that there is insufficient data on clinical utility
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and cost-effectiveness [39]. All guidelines recognized the potential of multi-gene testing but also
acknowledged the need for additional research on clinical utility of such tests in different conditions.
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Table 2. Coverage policies for pharmacogenomic tests guiding cancer treatments by Medicare contractors (n = 8) and private payers (n = 10).
Number of Policies that Mention & Cover the Test Number of Insurers that Cover the Test Covered Conditions Key References Cited in Coverage Policies CPT Codes Specified in Policies
Medicare Private Medicare Private Medicare Private Medicare Private Medicare Private
KRAS 6 12 6 9
mCRC 3
NSCLC
CML
ALL
mCRC 3
Adeno-
carcinoma
NSCLC
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
BCBSA TEC;
EGAPP; ASCO;
NCCN; ACG;
CAP TEC
81275-276
81311
81405-406
81275-276 2
81405
HER2 1 6 1 6
Breast cancer 3
Gastric
adenocarcinoma
Breast cancer 3
Gastric
adenocarcinoma
NSCLC
NCCN; ASCO;
CDC; AHRQ;
AMA; USPSTF
Hayes; NCCN;
NICE; ECRI; ASCO;
BCBSA TEC;
USPSTF; ACMG;
AHRQ
None 8395088360-361 1
BRAF 4 11 4 8
Melanoma 3
NSCLC
Hairy cell
leukemia
CRC
Brain cancer
Thyroid cancer
Ovarian/
uterine cancer
Melanoma 3
NSCLC
GISTs
mCRC
Hairy cell
leukemia
Lynch syndrome
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
FDA; BCBSA TEC;
NCCN; AHRQ;
EGAPP
81210
81210 2
88363
81406
EGFR 4 12 4 9 NSCLC
3
Brain cancer
NSCLC 3
CNS cancers
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
ASCO; CAP;
NCCN; FDA;
CAP/IASLC/AMP
81235 81235 2
ALK 2 10 2 9 NSCLC 3
NSCLC 3
Lymphoma
IMT
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
NCCN; NIH;
ASCO None
81401 1
81479
88271
88274
88291
88367-368
BCR-ABL1 3 8 3 8
CML 3
ALL 3
CMML
CML 3
ALL 3
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
WHO; FDA;
NCCN; AHRQ;
NCI; ACS;
AMP; Hayes
81206-208
81219
81270
81402-403
88170
88275
81206-208 2
81401
88271
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Table 2. Cont.
Number of Policies that Mention & Cover the Test Number of Insurers that Cover the Test Covered Conditions Key References Cited in Coverage Policies CPT Codes Specified in Policies
Medicare Private Medicare Private Medicare Private Medicare Private Medicare Private
c-Kit 2 3 2 3
GISTs 3
Melanoma
AML
ALL
MDS
GISTs 3
Melanoma
AML
ALL
MDS
EGAPP; FDA; NCCN;
ASCO;
AHRQ; AMA;
USPSTF; CDC;
Palmetto
NCCN 81272-273 81272-273
1
88184
PDGFR 1 1 1 1 MDS/MPN
3
GISTs
MDS/MPN 3
GISTs
AHRQ; AMA;
CDC; USPSTF None None
81314
81404
CD20 0 2 0 2 N/A NHL 3
AMA;
Palmetto None None 88184
G6PD 2 0 2 0 None specified N/A AHRQ; CDC; USPSTF N/A 81247-249 N/A
CD25 0 0 0 0 N/A N/A N/A N/A N/A N/A
PML/RARA 2 3 2 2
Acute
promyelocytic
leukemia
Acute
promyelocytic
leukemia
AHRQ; CDC; USPSTF NCCN; FDA 81315-316 81315-316
1 Most commonly used CPT code for biomarker testing; 2 Specific CPT code for biomarker testing; 3 Indicates FDA approved indication. All coverage counts based on medical coverage
policies: last updated on 04/2017 for single gene tests; policies identified were dated from 08/2015 until 02/2017. Medicare contractors include Novitas, Noridian, Palmetto, Cahaba,
Wisconsin Physicians Service Insurance Corporation (WPSIC), National Government Services (NGS), Cigna Government Services (CGS), and First Coast. Private payers include Harvard
Pilgrim Health Care, United Healthcare, Anthem, Aetna, Cigna, Independence Blue Cross, Humana, Highmark, HCSC, and Blue Cross Blue Shield of Massachusetts. Abbreviations:
CPT-Current Procedural Terminology. Conditions: ALL-acute lymphoblastic leukemia, AML-acute myeloid leukemia, CML-chronic myeloid leukemia, GISTs-gastrointestinal stromal
tumors, IMT-inflammatory myofibroblastic tumor, MDS/MPN-myelodysplastic/myeloproliferative diseases, mCRC-metastatic colorectal cancer, NHL-Non-Hodgkin’s lymphoma, and
NSCLC-nonsmall cell lung cancer. References: ACG-American College of Gastroenterology, ACMG-American College of Medical Genetics and Genomics, ACS-American Cancer Society,
AHRQ-Agency for Healthcare Research and Quality, AMA-American Medical Association, AMP-Association for Molecular Pathology, ASCO-American Society of Clinical Oncology,
BCBSA TEC-Blue Cross Blue Shield Association Technology Evaluation Center, CAP TEC- College of American Pathologists Technology Evaluation Center, CDC-Centers for Disease
Control and Prevention, ECRI-Emergency Care Research Institute, EGAPP-Evaluation of Genomic Applications in Practice and Prevention, IASLC-International Association for the
Study of Lung Cancer, NCCN-National Comprehensive Cancer Network, NCI-National Cancer Institute, NICE-National Institute for Health and Care Excellence, USPSTF-United States
Preventive Services Task Force, and WHO-World Health Organization.
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Table 3. Multi-gene testing recommendations by Professional Society Guidelines.
Society, Published Year Indications Mentioned Criteria/Reasoning References Cited
Recommend Multi-gene
Testing
ACMG, 2013 None specified
Targeted multi-gene testing is recommended for genetically heterogeneous
disorders and oncology applications. By limiting the content of the test to just the
regions relevant to a given disease, the resulting data usually have higher
analytical sensitivity and specificity for detecting mutations.
NIH, College of American Pathologists
ASCO, 2015 None specified
Testing option recommendations:
• Multi-gene testing may be efficient in circumstances that require evaluation
of multiple high-penetrance genes of established clinical utility
• Panel testing may identify mutations in genes associated with cancer risks
and mutations in high-penetrance genes
• Somatic mutation profiling can identify driver mutations in the cancer that
could serve as treatment targets
Tests being done to guide cancer treatment are often time sensitive and should
only include those tests that guide therapy.
Management of individuals/families with mutations in moderately penetrant
genes must include:
• A review of the literature so that family can determine the most appropriate
screening/prevention plan
• Patients to have proper counseling, as the results of panel testing may not
always be straight-forward
• Challenges, risks, and benefits explained to patients prior to testing
• Patient preferences should be included in decision making regarding the
most appropriate test
NIH, Cigna, observational study (n = 194 and
586), cross-sectional study (n = 2158), online
surveys (n = 225)
CMTP, 2015
NSCLC, advanced stage solid
tumors, hematologic
malignancies
Testing of 5 or more genes is recommended with the following criteria:
• Must be clinically relevant as cited by NCCN or ASCO; OR
• be cited in the label of an FDA-approved companion diagnostic; AND
• is not more expensive than the cost of individual testing
Testing of 50 or more genes is recommended with the following
criteria/indications:
• NSCLC
• Rare, uncommon, or stage IV solid tumors, e.g., lung and pancreatic cancers
• Exhausted other treatment options (including unresponsiveness
of treatments)
NCCN, Palmetto, review article
NCCN, 2017 NSCLC
Broader molecular profiling with the goal of identifying rare driver mutations for
which effective drugs may already be available, or to appropriately counsel
patients regarding availability of clinical trials. Broad molecular profiling is a key
component of the improvement of care of patients with NSCLC.
ASCO, cohort study (n = 31), retrospective
observational study (n = 419)
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Table 3. Cont.
Society, Published Year Indications Mentioned Criteria/Reasoning References Cited
Do Not Recommend
Multi-gene Testing
BCBSA TEC, 2013 None specified
Limited studies, poor study designs, plus a number of practical issues pertinent to
application of molecular marker profiling have not been sufficiently resolved for
clinical implementation. For example, the relative accuracy and precision of
different DNA sequencing methods are under investigation and may exhibit
variability secondary to training and experience of laboratories and personnel.
Optimal informatics methods to handle large amounts of sequencing data and
reconstruct them into clinically actionable information displays remain
problematic.
Two clinical trials (n = 68 and 86),
observational study (n = 460), methods study
NICE, 2013 NSCLC
For non-Sanger sequencing based tests and for tests such as Therascreen EGFR
Pyro Kit and next generation sequencing, there is insufficient evidence and
therefore, no recommendations can be made on their use.
NCCN, systematic review and cost-effective
analysis
Years reflect most recent, available published guidelines mentioning or specific to molecular profiling/multi-gene testing.
J. Pers. Med. 2018, 8, 19 10 of 15
3.3. Multi-Gene Tests Related Coverage Policies
Table 4 summarizes coverage policies identified for cancer-related multi-gene tests. Policies
identified were dated from April 2016 until December 2017. Eight Medicare contractors had 20 policies
that mentioned and covered multi-gene tests. Specifically, six Medicare contractors covered multi-gene
testing for NSCLC. Six of eight Medicare contractors also covered multi-gene tests for acute
myelogenous leukemia (AML), myeloproliferative disease (MPD), and colorectal cancer (CRC).
Palmetto’s policies were frequently cited by other Medicare contractors. We did not find prior
authorization requirements for multi-gene tests by Medicare contractors.
Six of ten private payers covered multi-gene testing for cancer in ten different policies. Six
private payers specified coverage for NSCLC and two payers also covered multi-gene tests for
myelodysplastic syndromes. In addition, Blue Cross Blue Shield provided coverage for many other
indications including, but not limited to, colorectal cancer, gastrointestinal stromal tumors, and
melanoma. IBX, HCSC, and Highmark, which all use eviCore, also provide coverage for colorectal
cancer and melanoma. If a test was not covered, payers often cited limited clinical utility evidence as a
justification and classified the test as “investigational/experimental.” Seven private payers required
prior authorization for any multi-gene tests for cancer that is covered.
Overall, policies from both private payers and Medicare contractors that covered multi-gene tests
were based on clinical guidelines as well as studies of different types (including clinical trials, cohort
studies, clinical validation studies, expert opinions, editorials, and reviews such as GeneReviews).
Across both public and private payers, multi-gene testing for cancer is most commonly covered for
NSCLC, which is consistent with recommendations from NCCN, the predominant guideline for cancer.
Payers varied in their coverage of multi-gene testing for other cancers, which reflects the fact that
guidelines vary in their recommendations for the use of multi-gene tests in other cancers (Table 3).
Table 4. Coverage policies for cancer related multi-gene tests by Medicare contractors (n = 8) and
private payers (n = 10).
Medicare Private
Policy mentions & covers at least one multi-gene test 20 10
Policy mentions & does not cover any multi-gene tests or
covers only medically necessary genes within the panel 3 6
Payers require prior authorization for testing N/A 7
Payers that cover at least one multi-gene test for NSCLC 6 6
Payers that cover at least one multi-gene test for conditions
other than NSCLC 6 5
Covered conditions
Acute myelogenous leukemia
CRC
MPD
NSCLC
MPD
Thryoid cancer
NSCLC
Others 1
Key references cited FDA, NCCN, WHO, Palmetto
BCBSA TEC, ECRI, Hayes Inc, NCCN,
NICE, SGO, NCI, FDA, ACOG, USPSTF,
ACS, ANZHSN, ASCO, ACMG
All coverage counts based on medical coverage policies; last updated on 12/2017 for multi-gene tests; policies
identified were dated from 04/2016 until 12/2017; Medicare contractors include First Coast, Cahaba, CGS, National
Government Services, Noridian, Novitas, Palmetto, and Wisconsin Physicians Services Insurance Company; Private
payers include Aetna, Blue Cross Blue Shield of Massachusetts (BCBS), Anthem, Cigna, Harvard Pilgrim Health Care,
HCSC, Highmark, Humana, Independence Blue Cross, and United Healthcare. 1 BCBS covers many indications
including: Solid Tumor NGS Panel: B-Cell NHL, bladder urothelial carcinoma, breast cancer, cholangiocarcinoma,
endometrial carcinoma, GI stromal tumor, glioma, medulloblastoma, melanoma, meningioma, neuroblastoma,
rare tumors, stomach/esophageal cancer, T-cell NHL, acute myeloid leukemia, B-ALL, B-cell NHL, myelodysplasia,
myeloproliferative diseases, T-ALL, and T-Cell NHL. Abbreviations: ACOG-American College of Obstetricians and
Gynecologists; ACS-American Cancer Society; ANZHSN-Australia and New Zealand Horizon Scanning Network;
CRC-colorectal cancer; MPD-myeloproliferative disease; SGO-Society of Gynecologic Oncology.
4. Discussion
Genomic tests are increasingly used in clinical care and the associated businesses are booming.
Insurance coverage policies can help govern the use of available resources for the population
and support access to clinically valuable testing [40]. This study focused on insurance policies
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for guideline-recommended pharmacogenomic tests for cancer, either as single or multi-gene tests.
We found substantial variations in how payers cover and manage pharmacogenomic testing for single
gene tests as well as multi-gene tests, with more variations among private payers than Medicare
contractors. Private payers commonly use prior authorization for these tests. Finally, we found
discrepancies among coverage policies and clinical guidelines for multi-gene tests.
Variations in coverage policies among payers for single gene tests were present even though the
pharmacogenomic tests included in the study were recommended by major guidelines for clinical
implementation based on evidence [6]. It is important to note, however, lack of explicit policies do
not necessarily translate to barriers to access for these single gene tests because Medicare contractors
and private payers often do not have policies for specific genomic tests. Our interview study found
that some payers do not view policies as necessary when clinical benefits are clear because policy
development is time and resource intensive [41]. Perhaps this is not out of the ordinary given that
many nongenetic medical services do not have specific policies beyond general statements about
“medical necessity.”
Multi-gene testing is currently being used in clinical practice and could possibly be more widely
used than single gene testing because of its potential to detect genomic alterations in hundreds of
cancer-related genes. We found variations in coverage of multi-gene testing across private payers but
relatively smaller variations among Medicare contractors. There are several possible explanations for
observed variations. First, while two major guidelines recommend the use of multi-gene testing for
NSCLC (including NCCN, the predominant guideline for cancer), one guideline does not recommend
the use of multi-gene testing for NSCLC and two others do not specify an indication for testing. It is not
surprising that six of 18 payers did not have policies for multi-gene tests for NSCLC. Coverage of
multi-gene testing for other cancers is highly variable, which reflects the fact that guidelines vary in
their recommendation for testing in other cancers. Second, there is limited evidence [17,38,42] on the
clinical utility of multi-gene tests. Evidence cited by guidelines differs such that no guidelines cite
the same studies, possibly due to the availability of published studies at the time of the assessment.
The limited evidence and lack of clinical consensus prevent payers from judging whether a multi-gene
test meets payers’ standards of medical necessity. The need for more research to generate evidence on
clinical utility of multi-gene tests is widely recognized [17]. Third, payers’ consideration of different
study types and interpretation of evidence could lead to differences in coverage. Few randomized
controlled trials assessed the clinical utility of multi-gene tests given the complexities of such tests.
Payers that cover multi-gene tests for NSCLC based their policies on clinical guidelines as well as
a wide range of studies beyond randomized controlled trials including clinical validation studies,
cohort studies, editorials, and reviews [43]. Finally, insurance coverage decisions are complex and they
are based on evidence (including clinical utility evidence, and analytic and clinical validity information)
as well as nonscientific factors (e.g., needs of the membership and lab contracting considerations),
which are not outlined in coverage policies [41].
Importantly, we found that eight of ten private payers require prior authorization for all genomic
testing, including single and multi-gene tests, to review medical necessity. Prior authorization generally
obligates physicians to provide information on clinical indication and to specify gene(s) to be tested
and patients to receive genetic counseling before and after genetic testing. Prior authorization is
used to address the concern that, because multi-gene tests include a large number of genes, there
is lack of transparency relating to the genes included in the panel tests [17,41,42]. Payers may
determine the multi-gene test to be ‘investigational’ based on the combination of genes included
that vary in their clinical utility. This concern relates to apprehensions about the numerous variants of
unknown significance that might be reported to physicians. Such information may change physicians’
recommendation and influence patients’ decision to seek care that may not be appropriate. In order
to grapple with the exponential growth in the types of tests and their growing use, and the limited
expertise in this complex field [41], payers employ laboratory benefit management (LBM) companies
to manage prior authorization applications and test utilization. This has occurred in other sectors of
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health care, for instance, pharmacy benefit management. The use of prior authorization is not limited
to those payers who have contracted with an LBM. Of the eight private payers that require prior
authorization for single gene and/or multi-gene testing, two do not use an LBM.
Variations in coverage policies and prior authorization requirements among payers create
confusion for patients and clinicians as to who has access to these tests and how they are used in
clinical practice [16]. We have several recommendations to reduce confusion and coverage variations.
First, understanding of payer coverage needs to be improved for genomic tests through ongoing,
systematic analyses of coverage policies and structured reporting. Coverage policies have a significant
role in determining patient access to genomic tests but, as demonstrated by our study, they are
extremely complex. Payers present information differently in their policies; for instance, some include
a range of genomic tests in the same policy and some may require use of specific test products
(e.g., Cologuard, Therascreen for KRAS). Registries of coverage policies, such as our own registry and
the TRANSPERS Payer Coverage Policy Registry [17], can provide an objective, structured tool for
research to examine coverage policies across payers, diseases or tests. These studies could facilitate
greater transparency in payer coverage decision-making, identify evidence gaps, and enhance patient
access to proven genomic tests. In addition to coverage policies, our registry also captures valuable
information on prior authorization and major clinical guidelines. While prior authorization can help
ensure appropriate use of genomic tests, it can also affect access to tests. Furthermore, it is important
to examine whether coverage policies are consistent with clinical guidelines. Maintaining and keeping
this type of registry up-to-date is a major undertaking, as the policies, prior authorization requirements,
and guidelines are updated as evidence accumulates and/or as demand from patients and clinicians
for access to genomic tests increases. Second, a single agency with appropriate expertise to assess
evidence for coverage decisions, such as Hayes Inc., could reduce variations in coverage across payers.
For instance, coverage for cancer-related multi-gene testing by Medicare contractors is relatively
consistent because other Medicare contractors often adopt Palmetto’s assessments of genomic tests,
whereas substantial variations exist among private payers as they make their coverage decisions and
policies independently. In addition, the use of LBM companies by payers is rapidly expanding to meet
the need for systemization of evidentiary review and automate updates to keep up with the deluge of
data in the literature [41]. Finally, increased dialogue and sharing of information among payers could
also create a more harmonious and uniform system.
The strength of our study is that it is one of the first to systematically analyze the coverage of
guideline-recommended pharmacogenomic tests for cancer, either as single or multi-gene tests, as well
as discrepancies among coverage policies and clinical guidelines. Nevertheless, this study has several
limitations. First, we included all Medicare contractors but not state Medicaid programs (Medicaid
programs provide health insurance to low-income citizens across the US). We included only 10 private
payers; however, we deliberately selected the top private payers across the US that provide coverage
for about 182.3 million individuals. We also included major guidelines available publicly; however,
there are other sources used by payers that we do not subscribe to and are therefore not included in
the study (e.g., Hayes Inc., Lansdale, PA, USA). Second, we focused on tumor markers for guiding
cancer treatments and those that were classified by CDC as tier-1 category. We did not attempt to
examine insurance coverage for multi-gene tests unrelated to these tumor makers; thus, access to many
multi-gene tests was beyond the scope of this study (e.g., multi-gene tests for Lynch Syndrome) [17].
Third, our analysis of published coverage policies did not aim to describe comprehensively the
complexity of coverage decision making. There are inherent limitations of published coverage policies
as these documents do not discuss all the factors that determine coverage, including judgment in the
interpretation of evidence. Fourth, the FDA recently approved a next generation sequencing-based
in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in
solid tumors [44]. The CMS also finalized a national coverage determination for this next generation
sequencing-based diagnostic test [45]. The FDA’s approval and CMS coverage for this multi-gene
test is a big step forward in genomic health care and could influence future coverage and utilization
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of multi-gene tests (for cancer and beyond). Finally, coverage policies do not directly translate to
reimbursement (e.g., whether prior authorization for the individual patient is approved).
5. Conclusions
Genomic tests are increasingly used in clinical care and the associated businesses are booming.
Insurance coverage policies can help govern the use of available resources for the population and
support access to clinically valuable testing. Our findings of variations in how payers are addressing
pharmacogenomic tests and the common use of prior authorization underscore the need for additional
research into the impact of these variations on cancer care and outcomes. Ongoing systematic analyses
of coverage policies and prior authorization requirements considering key clinical recommendations
are needed to improve understanding of access to and use of genomic tests.
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